The analysis of samples containing Respiratory Syncytial Virus (RSV) in clinical trials is notoriously challenging due to the virus's inherent instability.
hVIVO’s proprietary Stabilization Transport Matrix (STM) has been designed to meet this challenge, enabling RSV transport and stabilization in an array of clinical sample types, including nasopharyngeal swab and nasal wash samples.
The new STM from hVIVO has already achieved several notable milestones:
It has the capacity to maintain RSV viral RNA copies and RSV infectious titers at a dynamic range of up to eight hours at room temperature, affording clinical sites increased flexibility prior to sample processing.
It is able to maintain RSV viral RNA copies and RSV infectious titers at a dynamic range up to five weeks at -20 °C, enabling the bulk shipments of samples and affording clinical trial sites increased flexibility in terms of their cryostorage requirements.
The new STM is also able to maintain RSV viral RNA copies and RSV infectious titers at a dynamic range up to nine months at -80 °C, facilitating the testing of larger batches of clinical trial samples.
The matrix maintains stability and effectiveness at room temperature for up to nine months, facilitating the long-term storage of clinical trial collection kits and ensuring the minimal number of kit shipments at each site, as well as their tracking.
hVIVO’s STM affords its users increased operational flexibility in terms of RSV clinical sample collection and storage without the loss of viral infectivity. These powerful capabilities make this new STM an ideal choice for both RSV clinical trials and challenge studies.
Acknowledgments
Produced from materials originally authored by hVIVO.